Physician profile
James E Turek
NPI 1942360672
$4,834.54
in general payments reported to CMS, 2019-2025
37 companies · $962 in 2025
The $962 reported for 2025 was more than what 91% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $328 · 2021: $603 · 2022: $516 · 2023: $954 · 2024: $813 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.33 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.24 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Novo Nordisk INC | $547.45 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $463.01 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $449.02 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $337.55 | 2019-2024 | |
| Amarin Pharma, INC. | $227.25 | 2019-2021 | |
| Daiichi Sankyo INC. | $214.35 | 2019-2025 | Injectafer |
| Amgen INC. | $209.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $200.65 | 2023-2025 | Cologuard Collection Kit |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Dexcom, INC. | $134.74 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $131.28 | 2025 | |
| Allergan, INC. | $103.37 | 2019-2021 | |
| Abbott Laboratories | $100.48 | 2022-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $85.02 | 2022-2025 | Mounjaro, Zepbound |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Turek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.